title: Comments on the Salmeterol Multicenter Asthma Research Trial.
authors.forename: Sally M
authors.initials: SM
authors.lastname: Seymour
authors.forename: Eugene J
authors.initials: EJ
authors.lastname: Sullivan
authors.forename: Badrul A
authors.initials: BA
authors.lastname: Chowdhury
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Meyer
authors.forename: Ruthanna C
authors.initials: RC
authors.lastname: Davi
mesh_terms: D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D064420:Drug-Related Side Effects and Adverse Reactions; D023381:Endpoint Determination; D006801:Humans; D008432:Mathematical Computing; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D015203:Reproducibility of Results; D012307:Risk Factors; D000068299:Salmeterol Xinafoate; D015996:Survival Rate; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D000420:Albuterol